August 16, 2018 — Lexington Biosciences Inc. recently announced the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo Clinical Research.
As part of the clinical study protocol, the data acquired from this initial study of the HeartSentry device effectively provides critical guidance for key aspects of the pivotal study itself. With the conclusion of the initial term of work at Diablo Clinical Research, the company moves ahead under the continued leadership of Geoff Tison, M.D. M.P.H, into an advanced stage multicenter trial.
Lexington Biosciences will immediately embark on the implementation of agreements with several trial locations which have been previously contacted as potential study sites. Tison will utilize the initial data to update patient examination protocols as required. Both he and the company will work with each facility to begin enrollment of a significantly larger patient sample from their respective clinical databases.
HeartSentry was designed as a diagnostic device offering a new approach to non-invasive measurement and monitoring of cardiovascular health by assessing the function of a patient’s vascular endothelium, the innermost lining of the cardiovascular system. Lexington Biosciences designed HeartSentry to be accurate, quick and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately for patients as a first-line evaluation of cardiovascular health.
For more information: www.lexingtonbiosciences.com
January 23, 2024 
